Johnson & Johnson annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Revenue Growth & History (JNJ)
Johnson & Johnson reported $94.19B in revenue for fiscal 2025, an increase of 6.05% from the previous fiscal year.
View full Johnson & Johnson company overviewJohnson & Johnson annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $94.19B | $5.37B | +6.05% |
| 2024 | 2024-12-29 | $88.82B | $3.66B | +4.30% |
| 2023 | 2023-12-31 | $85.16B | $5.17B | +6.46% |
| 2022 | 2023-01-01 | $79.99B | $1.25B | +1.59% |
| 2021 | 2022-01-02 | $78.74B | −$3.84B | −4.65% |
| 2020 | 2021-01-04 | $82.58B | $525.0M | +0.64% |
| 2019 | 2019-12-29 | $82.06B | $478.0M | +0.59% |
| 2018 | 2018-12-30 | $81.58B | $5.13B | +6.71% |
| 2017 | 2017-12-31 | $76.45B | $4.56B | +6.34% |
| 2016 | 2017-01-01 | $71.89B | $1.82B | +2.59% |
| 2015 | 2016-01-03 | $70.07B | −$4.26B | −5.73% |
| 2014 | 2014-12-28 | $74.33B | $3.02B | +4.23% |
| 2013 | 2013-12-29 | $71.31B | $4.09B | +6.08% |
| 2012 | 2012-12-30 | $67.22B | $2.19B | +3.37% |
| 2011 | 2012-01-01 | $65.03B | $3.44B | +5.59% |
| 2010 | 2011-01-02 | $61.59B | −$310.0M | −0.50% |
| 2009 | 2010-01-03 | $61.90B | −$1.85B | −2.90% |
| 2008 | 2008-12-28 | $63.75B | $2.65B | +4.34% |
| 2007 | 2007-12-30 | $61.09B | — | — |
Johnson & Johnson quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $25.31B | $1.57B | +6.60% |
| Q1 2026 | 2026-03-29 | $24.06B | $2.17B | +9.91% |
| Q4 2025 | 2025-12-28 | $24.56B | $2.04B | +9.08% |
| Q3 2025 | 2025-09-28 | $23.99B | $1.52B | +6.77% |
| Q2 2025 | 2025-06-29 | $23.74B | $1.30B | +5.77% |
| Q1 2025 | 2025-03-30 | $21.89B | $510.0M | +2.39% |
| Q4 2024 | 2024-12-29 | $22.52B | $1.13B | +5.26% |
| Q3 2024 | 2024-09-29 | $22.47B | $1.12B | +5.25% |
| Q2 2024 | 2024-06-30 | $22.45B | $928.0M | +4.31% |
| Q1 2024 | 2024-03-31 | $21.38B | $489.0M | +2.34% |
| Q4 2023 | 2023-12-31 | $21.39B | $1.46B | +7.30% |
| Q3 2023 | 2023-10-01 | $21.35B | $1.35B | +6.78% |
| Q2 2023 | 2023-07-02 | $21.52B | $1.30B | +6.45% |
| Q1 2023 | 2023-04-02 | $20.89B | $1.05B | +5.31% |
| Q4 2022 | 2023-01-01 | $19.94B | $10.17B | +104.10% |
| Q3 2022 | 2022-10-02 | $20.00B | −$3.34B | −14.32% |
| Q2 2022 | 2022-07-03 | $20.21B | −$3.10B | −13.29% |
| Q1 2022 | 2022-04-03 | $19.84B | −$2.48B | −11.12% |
| Q4 2021 | 2022-01-02 | $9.77B | −$12.71B | −56.53% |
| Q3 2021 | 2021-10-03 | $23.34B | $2.26B | +10.70% |
| Q2 2021 | 2021-07-04 | $23.31B | $4.98B | +27.14% |
| Q1 2021 | 2021-04-04 | $22.32B | $1.63B | +7.88% |
| Q4 2020 | 2021-01-04 | $22.48B | $1.73B | +8.33% |
| Q3 2020 | 2020-09-27 | $21.08B | $353.0M | +1.70% |
| Q2 2020 | 2020-06-28 | $18.34B | −$2.23B | −10.83% |
| Q1 2020 | 2020-03-29 | $20.69B | $670.0M | +3.35% |
| Q4 2019 | 2019-12-29 | $20.75B | $353.0M | +1.73% |
| Q3 2019 | 2019-09-29 | $20.73B | $381.0M | +1.87% |
| Q2 2019 | 2019-06-30 | $20.56B | −$268.0M | −1.29% |
| Q1 2019 | 2019-03-31 | $20.02B | $12.0M | +0.06% |
| Q4 2018 | 2018-12-30 | $20.39B | $199.0M | +0.99% |
| Q3 2018 | 2018-09-30 | $20.35B | $698.0M | +3.55% |
| Q2 2018 | 2018-07-01 | $20.83B | $1.99B | +10.57% |
| Q1 2018 | 2018-04-01 | $20.01B | $2.24B | +12.63% |
| Q4 2017 | 2017-12-31 | $20.20B | $2.09B | +11.54% |
| Q3 2017 | 2017-10-01 | $19.65B | $1.83B | +10.27% |
| Q2 2017 | 2017-07-02 | $18.84B | $357.0M | +1.93% |
| Q1 2017 | 2017-04-02 | $17.77B | $284.0M | +1.62% |
| Q4 2016 | 2017-01-01 | $18.11B | $295.0M | +1.66% |
| Q3 2016 | 2016-10-02 | $17.82B | $718.0M | +4.20% |
| Q2 2016 | 2016-07-03 | $18.48B | $695.0M | +3.91% |
| Q1 2016 | 2016-04-03 | $17.48B | $108.0M | +0.62% |
| Q4 2015 | 2016-01-03 | $17.81B | −$443.0M | −2.43% |
| Q3 2015 | 2015-09-27 | $17.10B | −$1.36B | −7.39% |
| Q2 2015 | 2015-06-28 | $17.79B | −$1.71B | −8.76% |
| Q1 2015 | 2015-03-29 | $17.37B | −$741.0M | −4.09% |
| Q4 2014 | 2014-12-28 | $18.25B | −$101.0M | −0.55% |
| Q3 2014 | 2014-09-28 | $18.47B | $892.0M | +5.08% |
| Q2 2014 | 2014-06-29 | $19.50B | $1.62B | +9.05% |
| Q1 2014 | 2014-03-30 | $18.11B | $610.0M | +3.48% |
| Q4 2013 | 2013-12-29 | $18.36B | $797.0M | +4.54% |
| Q3 2013 | 2013-09-29 | $17.57B | $523.0M | +3.07% |
| Q2 2013 | 2013-06-30 | $17.88B | $1.40B | +8.51% |
| Q1 2013 | 2013-03-31 | $17.50B | $1.37B | +8.46% |
| Q4 2012 | 2012-12-30 | $17.56B | $1.30B | +8.02% |
| Q3 2012 | 2012-09-30 | $17.05B | $1.05B | +6.54% |
| Q2 2012 | 2012-07-01 | $16.48B | −$122.0M | −0.74% |
| Q1 2012 | 2012-04-01 | $16.14B | −$34.0M | −0.21% |
| Q4 2011 | 2012-01-01 | $16.25B | $611.0M | +3.91% |
| Q3 2011 | 2011-10-02 | $16.00B | $1.02B | +6.83% |
| Q2 2011 | 2011-07-03 | $16.60B | $1.27B | +8.26% |
| Q1 2011 | 2011-04-03 | $16.17B | $542.0M | +3.47% |
| Q4 2010 | 2011-01-02 | $15.64B | −$907.0M | −5.48% |
| Q3 2010 | 2010-10-03 | $14.98B | −$99.0M | −0.66% |
| Q2 2010 | 2010-07-04 | $15.33B | $91.0M | +0.60% |
| Q1 2010 | 2010-04-04 | $15.63B | $605.0M | +4.03% |
| Q4 2009 | 2010-01-03 | $16.55B | — | — |
| Q3 2009 | 2009-09-27 | $15.08B | −$840.0M | −5.28% |
| Q2 2009 | 2009-06-28 | $15.24B | −$1.21B | −7.36% |
| Q1 2009 | 2009-03-29 | $15.03B | — | — |
| Q3 2008 | 2008-09-28 | $15.92B | — | — |
| Q2 2008 | 2008-06-29 | $16.45B | — | — |
Johnson & Johnson revenue growth trends
Over the last five reported fiscal years, revenue grew from $82.58B to $94.19B, a compound annual growth rate of 2.67%. Johnson & Johnson's latest reported quarter, Q2 2026, generated $25.31B in revenue, an increase of 6.60% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Johnson & Johnson source filings ↗Community posts
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
